| Dr Jonathan Andrew Bolles, MD | |
|
1201 S Miller St Ste A, Wenatchee, WA 98801-3201 | |
| (509) 663-8711 | |
| Not Available |
| Full Name | Dr Jonathan Andrew Bolles |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 23 Years |
| Location | 1201 S Miller St Ste A, Wenatchee, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003839093 | NPI | - | NPPES |
| P01096688 | Other | WA | RR MEDICARE WVH |
| 1003839093 | Medicaid | WA | |
| 315727 | Other | WA | WVH LNI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 23017 (Nebraska) | Secondary |
| 207RC0000X | Internal Medicine - Cardiovascular Disease | MD60260896 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Central Washington Hospital | Wenatchee, WA | Hospital |
| Mid Valley Hospital | Omak, WA | Hospital |
| North Valley Hospital | Tonasket, WA | Hospital |
| Three Rivers Hospital | Brewster, WA | Hospital |
| Lake Chelan Community Hospital | Chelan, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Central Washington Health Services Association | 4880504596 | 645 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at The Parkinson's Institute and the Mayo Clinic have published new research findings in the journal Public Library of Science (PLoS). The new data show effective silencing of the alpha-synuclein gene with an RNAi therapeutic administered directly to the substantia nigra in the CNS of non-human primates.
Researchers at The University of Texas M. D. Anderson Cancer Center found that a simple test that can be administered and read in the doctor's office was three times more effective than a conventional laboratory test for detecting bladder cancer.
On-X Life Technologies, announced today that it has received approval from the U.S. Food and Drug Administration to market the On-X Ascending Aortic Prosthesis with the Vascutek Gelweave Valsalva Graft.
In children with autism, repetitive behaviors and gastrointestinal problems may be connected, new research has found.
› Verified 8 days ago
| Entity Name | Central Washington Health Services Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801937453 PECOS PAC ID: 4880504596 Enrollment ID: O20031106000287 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at The Parkinson's Institute and the Mayo Clinic have published new research findings in the journal Public Library of Science (PLoS). The new data show effective silencing of the alpha-synuclein gene with an RNAi therapeutic administered directly to the substantia nigra in the CNS of non-human primates.
Researchers at The University of Texas M. D. Anderson Cancer Center found that a simple test that can be administered and read in the doctor's office was three times more effective than a conventional laboratory test for detecting bladder cancer.
On-X Life Technologies, announced today that it has received approval from the U.S. Food and Drug Administration to market the On-X Ascending Aortic Prosthesis with the Vascutek Gelweave Valsalva Graft.
In children with autism, repetitive behaviors and gastrointestinal problems may be connected, new research has found.
› Verified 8 days ago
| Entity Name | Wenatchee Valley Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669719688 PECOS PAC ID: 9537309869 Enrollment ID: O20130716000034 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at The Parkinson's Institute and the Mayo Clinic have published new research findings in the journal Public Library of Science (PLoS). The new data show effective silencing of the alpha-synuclein gene with an RNAi therapeutic administered directly to the substantia nigra in the CNS of non-human primates.
Researchers at The University of Texas M. D. Anderson Cancer Center found that a simple test that can be administered and read in the doctor's office was three times more effective than a conventional laboratory test for detecting bladder cancer.
On-X Life Technologies, announced today that it has received approval from the U.S. Food and Drug Administration to market the On-X Ascending Aortic Prosthesis with the Vascutek Gelweave Valsalva Graft.
In children with autism, repetitive behaviors and gastrointestinal problems may be connected, new research has found.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jonathan Andrew Bolles, MD 820 N Chelan Ave, Wenatchee, WA 98801-2028 Ph: (509) 663-8711 | Dr Jonathan Andrew Bolles, MD 1201 S Miller St Ste A, Wenatchee, WA 98801-3201 Ph: (509) 663-8711 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at The Parkinson's Institute and the Mayo Clinic have published new research findings in the journal Public Library of Science (PLoS). The new data show effective silencing of the alpha-synuclein gene with an RNAi therapeutic administered directly to the substantia nigra in the CNS of non-human primates.
Researchers at The University of Texas M. D. Anderson Cancer Center found that a simple test that can be administered and read in the doctor's office was three times more effective than a conventional laboratory test for detecting bladder cancer.
On-X Life Technologies, announced today that it has received approval from the U.S. Food and Drug Administration to market the On-X Ascending Aortic Prosthesis with the Vascutek Gelweave Valsalva Graft.
In children with autism, repetitive behaviors and gastrointestinal problems may be connected, new research has found.
› Verified 8 days ago
Dr. Ahmad Sabih Musmar, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 933 Red Apple Rd, Wenatchee, WA 98801 Phone: 509-663-8711 | |
Brett J. Hiendlmayr, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1201 S Miller St, Wenatchee, WA 98801 Phone: 509-662-1511 | |
Kevin Joseph Struzzieri, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1201 S Miller St, Wenatchee, WA 98801 Phone: 509-663-8711 | |
Dr. Brent A. Barber, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 933 Red Apple Rd, Wenatchee, WA 98801 Phone: 509-663-8711 | |
Mircea Batanoiu, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711 Fax: 509-665-6065 | |
Dr. Mark Douglas Johnson, M.D., MTM&H Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 933 Red Apple Rd, Wenatchee, WA 98801 Phone: 509-665-6210 Fax: 509-667-3310 |